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A polypeptide in preparations of ‘large’ form (MI - 14000) material with inhibin-like activity (inhibiting 
FSH secretion) has been isolated from human seminal plasma. Its amino acid composition, cleavage 
pattern with CNBr, N-terminal sequence, and properties on reverse-phase high-performance liquid 
chromatography establish this inhibin-like preparation to be homogeneous. The polypeptide contains close 
to 130 residues, has a free N-terminal serine residue, a methionine residue in position 19, and a dibasic 
structure (Arg-Lys) in positions 16-17. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The secretion of follicle stimulating hormone 
(FSH) is not regulated entirely by the negative 
feed-back from gonadal steroids. The steroids can 
suppress FSH secretion, but they would then also 
affect secretion of luteinizing hormone (LH). A 
testicular factor (non-steroidal, water-soluble pep- 
tide) has been implicated in the negative feed-back 
control of FSH secretion and has been named in- 
hibin [l]. Several peptides with inhibin-like activi- 
ty, but differing in size and purification pattern, 
depending on organ and species, have been 
detected from gonads and their secretions (cf. 
reviews [2-41). A high-ill, form (Mr -14000) from 
human seminal plasma [5] has been reported, as 
well as low-M, forms (Mr < 2000) in sheep testes 
and ovaries [6,7]. The purification and general 
characterization of the polypeptide corresponding 
to the large form are described, together with the 
N-terminal amino acid sequence of the peptide, 
giving for the first time any structural information 
on a molecule with inhibin-like activity. 
2.1. Polypeptides 
Large-form inhibin-like polypeptide was 
prepared as in [5] with some modifications. Brief- 
ly, the procedure is as follows: The active material 
was precipitated from pooled seminal plasma using 
4 vols of ethanol. The precipitate was dissolved in 
sodium acetate buffer (pH 4.0) and loaded on a 
Sephadex G-100 column (90 x 2.5 cm), using the 
acetate buffer for elution. The fractions enriched 
in inhibin-like activity (detectable by bioassay, cf. 
below) were further purified on a 
DEAE-Sephadex A-50 clumn (60 x 1.5 cm) using 
step-wise elution with NaCl (0.02-0.05-0.1 M) in 
0.05 M Tris (pH 7.2). The material eluted with 
0.05 M NaCl gave a single band on sodium 
dodecyl sulphate polyacrylamide gel elec- 
trophoresis (SDS-PAGE) at pH 8.3 in 
Tris-glycine buffer, as in [3]. 
Reverse-phase high-performance liquid 
chromatography (RP-HPLC) was carried out us- 
ing a Waters system with a PBondapak Cl8 col- 
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umn in 0.1% trifluoroacetic acid with an 
acetonitrile gradient for elution as in [8]. 
2.2. B~o~ss~ys 
The biological activity of inhibin preparations 
was measured by the specific inhibition of FSH 
release in adult male rats and by in vitro incubation 
with rat pituitaries [9]. The purified fractions 
already gave positive reactions in these assays at 
amounts corresponding to about 100 ng and 10 ng 
polypeptide, respectively. These values are several- 
fold lower than those with other preparations 
reported in [9,10], suggesting high biological 
potency and purity of the present inhibin-Iike 
material. 
2.3. Structural analysis 
Carboxymethylation of the polypeptide 
(140 nmol) with 14C-labelled iodoacetate was car- 
ried out at pH 8.1 n 8 M urea, 0.1 M Tris, 2 mM 
EDTA (1.5 ml) after reduction with dithiothreitol 
(7.5 pmol, 37”C, 2 h) by reaction with 
iodo[2-r4C]acetate (22.5 rmol, 37”C, 1 h). Subse- 
quently, reagents were removed by extensive 
dialysis in Spectrapor 3 tubing against water. 
Cleavage with CNBr was performed in 70% formic 
acid as in [I 11. Chymotrypsin was used in 0.1 M 
ammonium bicarbonate for 4 h at 37°C at an en- 
zyme : inhibin CNBr-fragment ratio of 1: 10. 
Amino acid compositions were determined with a 
Beckman 12lM amino acid analyzer after 
hydrolysis in 6 M HCl, 0.5% phenol, at 110°C for 
24 h in evacuated tubes. Liquid phase sequencer 
degradations were performed in a Beckman 890D 
instrument in the presence of pre-cycled polybrene 
[ 121. Phenylthiohydantoin derivatives were iden- 
tified by high-performance liquid chromatography 
(HPLC) [13]. 
3. RESULTS 
3.1. High-Mr forpn of inhibin-like material 
A preparation containing the large form of 
inhibin-like material was obtained from seminal 
plasma by ethanol fractionation, exclusion 
chromatography on Sephadex G-100, and ion ex- 
change chromatography on DEAE-Sephadex [5]. 
This material, apparently homogeneous on 
SDS-PAGE [3], was submitted to RP-HPLC as 
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Fig.1. RP-HPLC of the large-form preparation of 
inhibin-like activity on FBondapak Cl8 in 0.1% 
trifluoroacetic acid and a gradient (@IO B) of acetonitrile 
(flow 1.5 ml/min). 
described in section 2. The result is shown in fig. 1, 
further indicating that the preparation of large 
form inhibin-like activity contains only one major 
peptide. This peptide is already largely pure before 
the step of HPLC. 
3.2. Characterization 
The polypeptide purified was “Q 
carboxymethylated with r4C-labelled iodoacetate 
in 8 M urea after reduction as described in section 
2. The total composition of the carboxymethylated 
polypeptide is given in table 1. Acceptable amino 
acid ratios are obtained with a minimum polypep- 
tide size of about 130 residues. This is in excellent 
agreement with the M, of 14000 estimated by 
SDS-PAGE against cytochrome c and myoglobin 
as standards. 
The composition suggests that the polypeptide 
contains one methionine residue (table 1). One ali- 
quot (70 nmol) was therefore cleaved with CNBr in 
70% formic acid. Subsequent exclusion 
chromatography on Sephadex G-50 in 30% acetic 
acid gave two peptide fractions as expected, frac- 
tion 1 eluting close to the void volume of the col- 
umn, and fraction 2 eluting much later but still 
well separated from low-M, UV-absorbing 
material derived from the reagents used. 
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Table 1 
Amino acid compositions of the polypeptide inlarge-form preparations of inhibin- 
like activity, its CNBr fragments, and the constituent chymotryptic peptides of the 
N-terminal CNBr fragment 
Peptide Whole 
polypeptide 
CNBr 1 CNBr 2 CNBr 2A CNBr 2B 
Qs(Cm) 9.6 (10) 6.3 (8) 1.3 (2) 1.0 (1) 0.8 (1) 
Asx 16.9 (17) 13.7 (15) 2.0 (2) - - 1.9 (2) 
Thr 9.5 (10) 8.4 (9) 1.1 (1) - - 0.9 (1) 
Ser 13.7 (13) 9.6 (11) 2.0 (2) 1.0 (1) 1.0 (1) 
Glx 20.1 (18) 15.1 (17) 1.2 (1) - - 1.2 (1) 
Pro 6.6 (7) 5.0 (5) 2.1 (2) - - 2.0 (2) 
Gly 11.2 (10) 8.4 (8) 2.2 (2) - - 2.1 (2) 
Ala 3.9 (4) 3.7 (4) - - - - - - 
Val 6.9 (7) 6.3 (6) 1.0 (1) - - 1.0 (1) 
Met 0.8 (1) - - 0.6 (1) - - + (1) 
Ile 6.1 (6) 5.2 (5) 1.0 (1) - - 0.9 (1) 
Leu 5.2 (5) 4.4 (5) - - - - - - 
Tyr 3.9 (5) 3.8 (4) 0.9 (1) 1.1 (1) - - 
Phe 3.0 (3) 2.0 (2) 1.0 (1) - - 0.9 (1) 
Trp 1.4 (1) + (1) - - - - - - 
Lys 11.2 (11) 9.9 (10) 1.0 (1) - - 1.1 (1) 
His 2.5 (2) 1.4 (2) - - - - - - 
Arg 3.2 (3) 1.7 (2) 0.8 (1) - - 0.9 (1) 
Sum -133 -114 19 3 16 
Intact carboxymethylated polypeptide (left column), the two CNBr fragments 
(CNBr 1 and CNBr 2), and the two chymotryptic peptides (CNBr 2A and 
CNBr 2B) were hydrolyzed with 6 M HCl, 0.5% phenol, for 24 h at 110°C; intact 
inhibin also with 4 M methanesulfonic acid, 0.2% 3-(2-aminoethyl)indole for the 
tryptophan analysis. Analytical values are molar ratios, with assumed integers 
within parentheses. Original Met in CNBr 2 and CNBr 2B was recovered as 
homoserine + homoserine lactone 
Fractions 1 and 2 both corresponded to pure 
fragments as shown by sequence analysis (below). 
The compositions of both fragments are given in 
table 1, and the two peptides appear to account for 
all residues present in the whole polypeptide. Fur- 
thermore, already the compositions show one of 
the fragments (fragment CNBr 2) to have, and one 
of them (fragment CNBr 1) to lack homoserine 
(table l), as expected for two major fragments 
from a parent polypeptide with one methionine 
residue. 
The whole polypeptide was submitted to direct 
liquid phase sequencer analysis as shown in table 2. 
Similarly, fragments CNBr 1 and CNBr 2 were 
also separately degraded. The residue in position 
18 was not fully identified from the sequencer 
degradations alone, and the composition of 
CNBr 2 was low in carboxymethylcysteine (table 1) 
suggested for that position (table 2). Therefore, 
one aliquot of CNBr 2 was cleaved with 
chymotrypsin. The two peptides obtained were 
separated by RP-HPLC and both were found to 
contain one residue of carboxymethylcysteine (also 
shown in table l), establishing the assignment in 
position 18. 
As shown in table 2, the results from the se- 
quencer degradations are consistent with the con- 
clusions from the compositions in showing frag- 
ment CNBr 2 to be derived from the N-terminal 
region of the polypeptide and fragment CNBr 1 to 
be derived from the remaining part by cleavage 
with CNBr at a methionine residue in position 19. 
13 
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N-terminal structure of the polypeptide in large-form preparations of inhibin-like 
activity as determined by liquid-phase sequencer analysis of the intact peptide, the 
N-terminal CNBr fragment from the 14C-carboxymethylated protein (CNBr 2 from 
the elution order on exclusion chromatography), and the second CNBr fragment 
(CNBr 1) 
Inhibin structure 
Position Residue 
deduced 
Analytical results 
Intact peptide CNBr 2 CNBR 1 
1 Ser 
2 Cys 
3 Tyr 
4 Phe 
5 Ile 
6 Pro 
7 Asn 
8 Glu 
9 Gly 
10 Val 
11 Pro 
12 GlY 
13 Asp 
14 Ser 
15 Thr 
16 Ar8 
17 Lys 
18 Cys 
19 Met 
20 Asp 
21 Leu 
22 Lys 
23 GUY 
24 Asn 
25 Lys 
26 His 
27 Pro 
28 Be 
29 Asn 
30 Ser 
Ser H 
- 
Tyr H 25 
Phe H 25 
Be H 30 
Pro H 
Asn H 
Glu H 
Gly H 
Val H 25 
Pro H 
Gly H 
Asp H 
Ser H 
Thr H 
Arg H 
Lys H 
_ 
Met H 20 
Asp H 
Leu H 20 
Lys H 
Gly H 
Asn H 
Lys H 
- 
Pro H 
Be H 15 
Asn H 
Ser H 
Ser H 
CysCm H R 
Tyr H 4 
Phe H 5 
Be H 5 
Pro H 
Asn H 
Glu H 
Gly H 
Val H 3 
Pro H 
Gly H 
Asp H 
Ser H 
Thr H 
Arg H 
Lys H 
(CysCm H R) 
Asp H 
Leu H 3 
Lys/Phe H 2 
Gly H 
Asn H 
Lys/Phe H 2 
His H 
Pro H 
- 
Residue identifications were by HPLC (H), and where applicable by radioactivity 
(R) for the 14C-carboxymethylated fragments. Values give nmol recovered of stable 
thiohydantoin derivatives from degradations of 5-40 nmol 
4. DISCUSSION total of about 130 residues. In addition, the N- 
terminal structure was established. The single band 
4.1. Homogeneity upon gel electrophoresis and the single peak upon 
The consistent results from sequence analysis, RP-HPLC (fig.1) also support purity of the star- 
CNBr cleavage and total compositions fully con- ting material. It may therefore be concluded that a 
firm that the present preparation with inhibin-like single polypeptide is the major component of large 
activity is essentially homogeneous in relation to a form preparations with inhibin-like activity from 
major polypeptide with N-terminal serine and a seminal plasma. 
14 
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